Selective blockade of serotonin(2C/2B) receptors enhances dopamine release in the rat nucleus accumbens

Neuropharmacology

Volumn 37, Issue 2, 1998, Pages 265-272

  Di Matteo, Vincenzo ^a   Di Giovanni, Giuseppe ^a   Di Mascio, Michele ^a   Esposito, Ennio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Dopamine release; Mesulergine; Nucleus accumbens microdialysis; RP 62203; SB 206553

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 3,4 DIHYDROXYPHENYLACETIC ACID; APOMORPHINE; FANANSERIN; MESULERGINE; RITANSERIN; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; INDOLE DERIVATIVE; NAPHTHALENE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; SULFOXIDE;

ANIMAL TISSUE; ARTICLE; DATA ANALYSIS; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; ANIMAL; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; APOMORPHINE; CYCLIC S-OXIDES; DOPAMINE; DOPAMINE AGONISTS; ERGOLINES; INDOLES; MICRODIALYSIS; NAPHTHALENES; NUCLEUS ACCUMBENS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RITANSERIN; SEROTONIN ANTAGONISTS;

EID: 0031987361     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00014-8     Document Type: Article

References (39)

1. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 179:1978;641-668.
2. Benloucif S., Galloway M.P. Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur. J. Pharmacol. 200:1991;1-8.
3. Boess F.G., Martin I.L. Molecular biology of 5-HT receptors. Neuropharmacology. 33:1994;275-317.
4. 4 receptor subtype involvement in the enhancement of striatal dopamine release induced by serotonin: a microdialysis study in the halothane-anesthetized rats. Neuropharmacology. 34:1995;269-279.
5. Cervo L., Grignaschi G., Samanin R. The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test. Eur. J. Pharmacol. 178:1990;129-133.
6. Cervo L., Samanin R. Evidence that dopamine mechanisms in the nucleus accumbens are selectively involved in the effect of desipramine in the forced swimming test. Neuropharmacology. 26:1987;1469-1472.
7. Cervo L., Samanin R. Repeated treatment with imipramine and amitriptyline reduced the immobility of rats in the forced swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J. Pharm. Pharmacol. 40:1988;155-156.
8. Deutch A., Moghaddam B., Innis R.B., Krystal J.H., Aghajanian G.K., Bunney B.S., Charney D.S. Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophrenia Res. 4:1991;121-156.
9. 2C receptors enhances mesostriatal and mesolimbic dopaminergic function. Trends Neurosci. (Suppl). 20:1997;59.
10. 2 receptor antagonist. Br. J. Pharmacol. 105:1992;27-36.
11. Ennis C., Kemp J.D., Cox B. Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J. Neurochem. 36:1981;1515-1520.
12. 2B receptor antagonist. J. Med. Chem. 38:1996;855-857.
13. Glennon R.A. Central serotonin receptors as targets for drug research. J. Med. Chem. 30:1987;1-12.
14. Hervé D., Pickel V.M., Tong H.J., Beaudet A. Serotonin axon terminals in the ventral segmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435:1987;71-83.
15. 1 recognition sites. J. Recept. Res. 8:1988a;59-81.
16. 1C receptors. Trends Pharmacol. Sci. 9:1988b;89-94.
17. 1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur. J. Pharmacol. 231:1993;223-229.
18. Kelland M.D., Freeman A.S., Chiodo L.A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J. Pharmacol. Exp. Ther. 253:1990;803-811.
19. Kelland M.D., Freeman A.S., Rubin J., Chiodo L.A. Ascending afferent regulation of rat midbrain dopamine neurons. Brain Res. Bull. 31:1993;539-546.
20. 1C receptors. Br. J. Pharmacol. 94:1988;137-147.
21. 2B receptor antagonist with anxiolytic-like properties. Br. J. Pharmacol. 117:1996;427-434.
22. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
23. 2C receptors inhibit the activity of mesocortical and mesolimbic dopaminergic pathways: a combined dialysis and electrophysiological analysis. Soc. Neurosci. Abstr. 23:1997;975, 386.13.
24. 2 antagonist. Mol. Pharmacol. 27:1985;600-611.
25. 2 receptor antagonist. In vitro and ex vivo selectivity profile. Eur. J. Pharmacol. 233:1993;29-35.
26. Merlo Pich E., Samanin R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology. 89:1986;125-130.
27. Moghaddam B., Bunney B.S. Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J. Neurochem. 53:1989;652-654.
28. Moore R.Y., Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu. Rev. Neurosci. 1:1978;129-169.
29. Mori S., Matsuura T., Takino T., Sano Y. Light and electron microscopic immunohistochemical studies of serotonin nerve fibers in the substantia nigra of the rat, cat and monkey. Anat. Embryol. 176:1987;13-18.
30. Paxinos, G., Watson, C., 1986. The Rat Brain In Stereotaxic Coordinates. Academic Press, New York.
31. Phillipson O.T. Afferent projections to the ventral segmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J. Comp. Neurol. 187:1979;117-144.
32. 2C receptors. Mol. Brain Res. 23:1994;163-178.
33. Prisco S., Pagannone S., Esposito E. Serotonin-dopamine interaction in the rat ventral segmental area: an electrophysiological study in vivo. J. Pharmacol. Exp. Ther. 271:1994;83-90.
34. 2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
35. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3-4-methylenedioxymethamphetamine. J. Neurochem. 62:1994;1382-1389.
36. Steinbusch, H.W.M., 1984. Serotonin-immunoreactive neurons and their projections in the CNS. Classical transmitters and transmitter receptors in the CNS. Part II. In: Bjorklund, A., Hokfelt, T., Kuhar, M.J. (Eds.), Handbook of Chemical Neuroanatomy, Vol. 3. Elsevier, Amsterdam, pp. 68-125.
37. 4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo. Br. J. Pharmacol. 117:1996;55-62.
38. Van Wijngaarden I., Tulp M.Th.M., Soudijn W. The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol. 188:1990;301-312.
39. Zetterström T., Sharp T., Ungerstedt U. Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo. Naunyn-Schmiedebergs. Arch. Pharmacol. 334:1986;117-124.